RecruitingOBSERVATIONAL

Molecular Tumor Board at the Center for Personalized Medicine Tübingen

This study is about a special team of experts, called a 'Molecular Tumour Board', at the University Hospital Tübingen. This team helps doctors decide the best treatments for people with advanced cancer by looking closely at the cancer's unique features. The study aims to keep a record of all patients referred to this board, carefully tracking how well their treatments work and how they feel over time. They want to see if the board's advice is followed by doctors in their everyday care. Ultimately, the goal is to understand and improve how personalised cancer treatments are given, leading to better care for patients in the future.

At a glance

Status

Recruiting

Sponsor

University Hospital Tuebingen

Enrolment target

1,000

Start

01 Mar 2018

Estimated completion

01 Mar 2028

Advanced Cancer

What is this study about?

Imagine specialists who look at the unique genetic makeup of your cancer, much like how every person has unique fingerprints. This study focuses on a team of such experts, called a 'Molecular Tumour Board', at the University Hospital Tübingen. This board helps your doctor decide on the very best treatment plan that’s tailored specifically for you, based on these unique details of your cancer.

This isn't a study where you'd be trying a new medication or treatment. Instead, it's about watching and learning from the care that's already being given. The main goals are to keep careful records of patients whose cases are discussed by this expert board. They want to see how patients respond to their treatments, how long they stay well, and how they feel overall. They also check to see if the recommendations made by the board are put into practice by the doctors.

The information gathered from this study will help doctors and researchers understand how this special way of planning treatment works in real life. By learning from each patient's journey, they hope to improve how personalised cancer care is offered in the future, making sure more people get the most effective and tailored treatment possible.

Key takeaways

This study observes how expert teams help tailor cancer treatment.
It aims to improve personalised cancer care for the future.
You won't receive new treatments or do anything extra.
Your medical information will be documented carefully.
Participation is voluntary and won't affect your care.

Who may be eligible?

To be part of this study, you need to be an adult, aged 18 or over. You must also have advanced cancer. Your doctor would need to have referred your case to the Molecular Tumour Board specifically because they need help understanding your cancer's unique features to plan your treatment.

Before you can take part, you'll need to give your permission by signing a form called 'informed consent'. This means you understand what the study is about and agree for your information to be used for research purposes.

This study is only for people with cancer. If you don't have cancer, or if your doctor hasn't asked the Molecular Tumour Board for advice about your treatment, then this study isn't for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have advanced cancer?
Has your doctor referred your case to a Molecular Tumour Board?
Are you willing to sign a consent form?

Answer every question to see your result.

What does participation involve?

Taking part in this study means that your care will be reviewed by the Molecular Tumour Board, and information about your treatment and health will be carefully recorded. You won't be given any new treatments or asked to do anything extra. This study is simply about observing and documenting the care you already receive when your doctor refers you to the Molecular Tumour Board.

There are no extra visits or assessments specifically for the study. Your doctors will continue to monitor your progress, such as how your cancer responds to treatment and how you are feeling, as they normally would. The study will just make sure this information is documented. The total duration of your participation would depend on how long your treatment and follow-up care continues under the guidance assisted by the Molecular Tumour Board.

Potential risks and benefits

Since this study is simply about observing and recording the usual care you receive under the guidance of the Molecular Tumour Board, there are no direct risks from participating in the study itself. You won't be given any experimental treatments or asked to do anything that isn't part of your regular medical care. The potential benefit is that the information gathered from your experience, along with many other patients, can help improve how cancer care is planned and delivered for future patients. You are always free to withdraw from the study at any time without it affecting your medical care.

Locations (1)

University Hospital Tübingen
Verified postcode
Tübingen, Germany· Recruiting

Common questions

What is a 'Molecular Tumour Board'?

It's a team of cancer experts who look at your cancer's unique genetic features to help your doctor decide on the best treatment for you.

Will I receive new treatment if I join this study?

No, this study doesn't involve any new or experimental treatments. It just observes and records the care you're already getting.

Do I need to do anything extra for this study?

No, you don't need to do anything extra. Your regular doctor's appointments and treatments will continue as normal.

Can I leave the study if I change my mind?

Yes, you can choose to stop participating in the study at any time without it affecting your medical care.

Who is running this study?

This study is being run by the Center for Personalized Medicine at the University Hospital Tübingen.

How to find out more

Ghazaleh Tabatabai, Prof

ghazaleh.tabatabai@med.uni-tuebingen.de 0049707129 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.